Pascal Bamford's most recent trade in Akoya Biosciences Inc was a trade of 196,250 Common Stock done . Disclosure was reported to the exchange on July 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Other type of transaction at price $ 0.00 per share. | 08 Jul 2025 | 196,250 | 0 | - | - | Common Stock | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Other type of transaction at price $ 0.00 per share. | 08 Jul 2025 | 150,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Other type of transaction at price $ 0.00 per share. | 08 Jul 2025 | 50,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Other type of transaction at price $ 0.00 per share. | 08 Jul 2025 | 25,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Other type of transaction at price $ 0.00 per share. | 08 Jul 2025 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Other type of transaction at price $ 0.00 per share. | 08 Jul 2025 | 9,488 | 196,250 | - | - | Common Stock | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.25 per share. | 01 Jun 2025 | 670 | 205,738 | - | 1.3 | 838 | Common Stock |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 01 Mar 2025 | 2,567 | 206,408 | - | 1.6 | 4,184 | Common Stock |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 01 Mar 2025 | 1,283 | 208,975 | - | 1.6 | 2,091 | Common Stock |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2024 | 87,500 | 210,258 | - | 0 | Common Stock | |
| Akoya Biosciences Inc | Pascal Bamford | Chief Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2024 | 40,000 | 122,758 | - | 0 | Common Stock |